Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma-Reference-Cited by-同舟云学术

Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma

Published:2020-06-04 Issue:23 Volume:135 Page:2106-2109
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Neelapu Sattva S.¹^ORCID,Jacobson Caron A.²,Oluwole Olalekan O.³^ORCID,Munoz Javier⁴,Deol Abhinav⁵,Miklos David B.⁶^ORCID,Bartlett Nancy L.⁷⁸,Braunschweig Ira⁹,Jiang Yizhou¹⁰,Kim Jenny J.¹⁰,Zheng Lianqing¹⁰,Rossi John M.¹⁰,Locke Frederick L.¹¹

Affiliation:

1. Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;

2. Hematologic Oncology Treatment Center, Dana-Farber Cancer Institute, Boston, MA;

3. Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN;

4. Department of Lymphoma/Myeloma, Banner MD Anderson Cancer Center, Gilbert, AZ;

5. Karmanos Cancer Center, Department of Oncology, Wayne State University, Detroit, MI;

6. Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA;

7. Department of Medicine, Washington University School of Medicine, St. Louis, MO;

8. Siteman Cancer Center, St. Louis, MO;

9. Montefiore Medical Center, Department of Oncology, Albert Einstein College of Medicine, Bronx, NY;

10. Kite, a Gilead Company, Santa Monica, CA; and

11. Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL

Abstract

Neelapu and colleagues report a post hoc subgroup analysis from the ZUMA-1 trial of chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B cell lymphoma. In comparison with younger patients, those ≥65 years old have similar rates of complete response and durable response at 2 years, but higher rates of neurological toxicity.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/135/23/2106/1743262/bloodbld2019004162.pdf

Reference14 articles.

1. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001;Morton;Blood,2006

2. A predictive model for aggressive non-Hodgkin’s lymphoma;Shipp;N Engl J Med,1993

3. National Comprehensive Cancer Network, Inc. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas, version 5.2019. Plymouth Meeting, PA: National Comprehensive Cancer Network, Inc; 2019. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed 4 November 2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Referenced with permission. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

4. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study [published correction appears in Blood. 2018;131(5):587-588];Crump;Blood,2017

5. Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis;Sun;Oncologist,2018

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Curative intent therapy for DLBCL in the elderly;Leukemia & Lymphoma;2024-01-11

2. Current development of chimeric antigen receptor T‐cell therapy for diffuse large B‐cell lymphoma and high‐grade B‐cell lymphoma;European Journal of Haematology;2024-01-03

3. Chimeric Antigen Receptor Therapy in Lymphoma;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024

4. Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas;Hematology;2023-12-08

5. Chimeric Antigen Receptor T-Cell Therapy in Aggressive B-Cell Lymphoma;Hematology/Oncology Clinics of North America;2023-12